ReviewStem cells international2017
Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia.
Review in Stem cells international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 53 citations in OpenAlex.
- The ER Stress-related Gene Prognostic Signature for Predicting Chemosensitivity and Prognosis in AML.Recent patents on anti-cancer drug discovery · 2026Article
- Genetic profile of ASXL1 gene in risk assessment in acute myeloid leukemia.BMC genomic data · 2025Article
- Acute Myeloid Leukemia with Normal Cytogenetics andBiomedicines · 2024Article
- Landscape of internal N7-methylguanosine of long non-coding RNA modifications in resistant acute myeloid leukemia.BMC genomics · 2023Article
- A novel scoring system for the quantitative prediction of prognosis in acute myeloid leukemia.Frontiers in oncology · 2023Article
- Concurrent Mutations inBiology · 2022Article
- Mutation profile of acute myeloid leukaemia in a Chinese cohort by targeted next-generation sequencing.Cancer reports (Hoboken, N.J.) · 2022Article
- High Frequency of ASXL1 and IDH Mutations in Young Acute Myeloid Leukemia Egyptian Patients.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Rapid Detection of N-RAS Gene Common Mutations in Acute Myeloid Leukemia (AML) Using High Resolution Melting (HRM) Method.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Novel combined variants of WT1 and TET2 in a refractory and recurrent AML patient.BMC medical genomics · 2021Article
- Article
- Loss-of-Function Mutations ofCancers · 2021Article
- Prognostic Prediction of Cytogenetically Normal Acute Myeloid Leukemia Based on a Gene Expression Model.Frontiers in oncology · 2021Article
- Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.PloS one · 2021Article
- [RUNX1 gene mutations are associated with adverse prognosis of patients with acute myeloidleukemia].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- Chronic loss of STAG2 leads to altered chromatin structure contributing to de-regulated transcription in AML.Journal of translational medicine · 2020Article
- Acidic leucine-rich nuclear phosphoprotein-32A expression contributes to adverse outcome in acute myeloid leukemia.Annals of translational medicine · 2020Article
- High IFITM3 expression predicts adverse prognosis in acute myeloid leukemia.Cancer gene therapy · 2020Article
- AberrantFrontiers in oncology · 2020Article
- Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.Blood advances · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult acute myeloid leukemia (AML) clinically is a disparate disease that requires intensive treatments ranging from chemotherapy alone to allogeneic hematopoietic cell transplantation (allo-HCT). Historically, cytogenetic analysis has been a useful prognostic tool to classify patients into favorable, intermediate, and unfavorable prognostic risk groups. However, the intermediate-risk group, consisting predominantly of cytogenetically normal AML (CN-AML), itself exhibits diverse clinical outcomes and requires further characterization to allow for more optimal treatment decision-making. The recent advances in clinical genomics have led to the recategorization of CN-AML into favorable or unfavorable subgroups. The relapsing nature of AML is thought to be due to clonal heterogeneity that includes founder or driver mutations present in the leukemic stem cell population. In this article, we summarize the clinical outcomes of relevant molecular mutations and their cooccurrences in CN-AML, including
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.